论文部分内容阅读
《New Engl J Med》1985,3121(14):915。链激酶对紧急溶解冠状动脉血凝块并不理想。它具有抗原性,半寿期较长,对纤维素蛋白的特异性较低,并能导致全身溶血状态。科学家对溶栓新药的产生非常感兴趣。新溶栓药对纤维素凝块比链激酶更具有特异性,抗原性也较弱,不可能有全身作用。这些药物中最有前途的是“组织型纤维蛋白溶酶原激活物(TPA)”,一种天然产生的蛋白酶,它能与纤维蛋白凝块结合后将纤维蛋白溶酶原转变为纤维蛋白溶酶,因此,主要增加在凝血块上的而不是血液循环中的纤维蛋白溶酶的浓度。目前为
New Engl J Med 1985, 3121 (14): 915. Streptokinase is not ideal for emergency dissolution of coronary blood clots. It has antigenicity, long half-life, low specificity for cellulose, and can lead to systemic hemolytic status. Scientists are very interested in the emergence of new drugs for thrombolysis. New thrombolytic drugs on cellulose clot more specific than streptokinase, antigenicity is also weak, can not have systemic effects. The most promising of these drugs is “tissue-type plasminogen activator (TPA),” a naturally occurring protease that converts fibrinolysis to fibrinolysis upon binding to fibrin clots The enzyme, therefore, mainly increases the concentration of plasmin on the clot instead of the blood circulation. Currently